miR‐21‐5p inhibits neuropathic pain development via directly targeting C‐C motif ligand 1 and tissue inhibitor of metalloproteinase‐3

MicroRNAs (miRNA) play important roles in neuroinflammation and neuropathic pain development; however, the underlying mechanism requires further investigation. The expression of miR‐21‐5p was remarkably upregulated in chronic constrictive injury (CCI) rat model. A significant alleviated neuropathic pain development and reduced the expression of cytokines was observed in CCI rat after exogenous injection of miR‐21‐5p mimic. The dual‐luciferase analysis revealed that tissue inhibitor of metalloproteinase‐3 (TIMP3) and chemokines C‐C motif ligand 1 (CCL1) was direct downstream target of miR‐21‐5p. Moreover, silencing of TIMP3 and CCL1 could rescue mechanical allodynia, thermal hyperalgesia and cytokine release in CCI rat, suggesting that TIMP3 and CCL1 exert their function by mediating neuroinflammation in neuropathic pain development. Therefore, we have identified a novel miR‐21‐5p–CCL1/TIMP3‐cytokine axis in regulation of neuropathic pain development in CCI rat model, which is valuable for enhancing our understanding of neuropathic pain and developing miRNAs as potential therapeutic options in the future. We have elaborated a miR‐21‐CCL1/TIMP3‐cytokine orchestration in regulation of neuropathic pain development in chronic constrictive injury (CCI) rat model. Our study consolidated the value of miR‐21 in neuropathic pain development, which could act as a potential therapeutic option for the treatment of neuropathic pain.